- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases
Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.